RBCC: Tech Innovations Drive Big Growth in $60 Billion Drug Delivery Market
13 March 2013 - 8:00PM
Business Wire
The next generation of advanced pharmaceutical technologies
could be poised to fuel remarkable growth in the $60 billion global
drug delivery market, and Rainbow Biosciences—the biotech
subsidiary of Rainbow Coral Corp. (OTCBB: RBCC)—plans to be right
in the middle of the action.
New drug delivery methods are seen by some pharmaceutical giants
as a crucial growth generator, and new innovations are spreading
across the healthcare sector. Many experts believe that
personalized medicine is the future of healthcare, and customized
drug delivery has the potential to drastically change the way value
is assessed and compensated in the U.S. healthcare system.
RBCC is working hard to capitalize on the changing drug-delivery
paradigm by partnering with key players in the field. The company
is now in talks with an emerging company that owns technology with
the potential to enable selective, site-specific delivery, allowing
for lower drug concentrations and greatly reducing the risk of drug
toxicity. In addition to helping millions of patients struggling
with chronic conditions, this bold new technology can also extend
the patent life cycles of drugs, giving potential pharmaceutical
partners a tremendous market advantage.
For more information on Rainbow BioSciences’ current projects,
please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research
technology innovations to compete alongside companies such as
Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc.
(NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen
Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of
Rainbow Coral Corp. (OTCBB: RBCC). The Company continually
seeks out new partnerships with biotechnology developers to deliver
profitable new medical technologies and innovations. For more
information on our growth-oriented business initiatives, please
visit www.RainbowBioSciences.com. For investment information and
performance data on the Company, please
visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995: This news release contains forward-looking
information within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including statements that include the words
"believes," "expects," "anticipate" or similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the Company to differ materially
from those expressed or implied by such forward-looking statements.
In addition, description of anyone's past success, either financial
or strategic, is no guarantee of future success. This news release
speaks as of the date first set forth above and the Company assumes
no responsibility to update the information included herein for
events occurring after the date hereof.